NexImmune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-32.34	-62.51	-51.28	-33.15	-23.21	-14.91
Depreciation & Amortization	1.56	1.5	0.87	0.62	0.44	0.2
Share-Based Compensation	3.55	5.87	5.98	1.22	1.53	1.21
Other Operating Activities	-4.2	3.95	-1.73	1.63	-0.84	0.3
Operating Cash Flow	-31.43	-51.19	-45.79	-26.4	-19.42	-11.12
Capital Expenditures	-0.04	-1.17	-2.35	-0.86	-1.25	-0.94
Acquisitions	0	0	0	0.08	0.01	0.11
Change in Investments	0	51.49	-51.46	1.01	10.66	-11.66
Other Investing Activities	-	-	-	-	-0	-0.15
Investing Cash Flow	-0.04	50.32	-53.81	0.22	9.42	-12.64
Share Issuance / Repurchase	0	5.18	115.89	0.01	0.21	0
Debt Issued / Paid	0	0	9	22.25	-0.02	-0.01
Other Financing Activities	-	-	-	-0.17	18.57	9.18
Financing Cash Flow	0	5.18	124.89	22.08	18.76	9.18
Net Cash Flow	-31.47	4.3	25.3	-4.1	8.77	-14.58
Free Cash Flow	-31.47	-52.37	-48.14	-27.27	-20.66	-12.06
Free Cash Flow Per Share	-29.99	-54.41	-59.62	-543.29	-416.40	-268.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).